DNAGinkgo Bioworks Holdings, Inc.
Price
-23%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth fading, the market undecided.
Charts
As reported to the SEC, without any scoring.
Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $20M in Q2 2026 (quarter ended Jun 30, 2026), down 48% from the same quarter a year earlier. That came with a gross margin of 91% and net loss of $47M. For the full year FY2025, revenue was $170M (−25% year on year) and net income −$313M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland.Earnings release · press release
- May 7, 2026Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab.Earnings release · press release
- Apr 7, 2026On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”) completed the previously announced transaction (the “Transaction”) with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the “Purchaser”) pursuant to the Stock Purchase …Acquisition or disposition completed · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.